JERUSALEM, Nov. 6, 2018 /PRNewswire/ -- Yissum, the Technology Transfer Company of The Hebrew University announced a novel technology for the 3D printing of drug capsules. The technology is based on custom-printed 3D hydrogels with delayed release characteristics. The technology will be presented at the 2nd annual conference, 3d Printing and Beyond, November 7, 2018, at the Hebrew University in Jerusalem.
Professor Shlomo Magdassi, head of the Hebrew University's 3D and Functional Printing Center, as well as a member of the Center for Nanoscience and Nanotechnology and Institute of Chemistry, in collaboration with Dr. Ofra Benny, researcher at Hebrew University's Institute for Drug Research, developed the cutting edge drug fabrication technology which enables a complex design of drug delivery systems, currently unavailable in conventional pharmaceutical manufacturing techniques. This approach enables printing customized and personalized medications out of hydrogel objects which can expand, change shape, and activate on a delayed schedule.
Besides the ability to achieve complex structures and release profiles of drugs, this novel platform has the ability to personalize prescription medicines, allowing for doctors to tailor accurately the exposure and dosage levels for individual patients.
"Professor Magdassi and Dr. Benny's research is an excellent example of the kind of interdisciplinary transformational inventions that originate from the Hebrew University. This technology is bringing us closer to a future in which the medical field can offer personalized, patient-centered care," said Dr. Yaron Daniely, CEO and President of Yissum.
3D printed hydrogels are just one of many innovations that will be presented at the 2nd annual conference, 3D Printing and Beyond, which brings to Jerusalem a wide range of global industry leaders and researchers to explore advances in pharmaceuticals, electronics, and defense related technologies, along with 3D printed food, automotive parts and more.
3D Printing and Beyond is organized by Prof. Shlomo Magdassi and Dr. Michael Layani of the 3D and Functional Printing Center at the Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem. The conference is sponsored by the Jerusalem Development Authority, Yissum, the Technology Transfer Company of The Hebrew University and The Hebrew University of Jerusalem.
About Yissum Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the third company of its kind to be established and serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum's mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,000 patents covering 2,800 inventions; licensed over 900 technologies and has spun out more than 135 companies. Yissum's business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il
About JNext Jnext is a joint initiative of the Ministry of Jerusalem and Heritage, the Jerusalem Development Authority, and the Jerusalem Municipality, and was established with the goal of developing and promoting entrepreneurship and the innovation ecosystem in Jerusalem. Jnext's brief is to make the city a congenial, supportive place for start-ups on a global level. Jnext promotes these objectives by supporting platforms that create original projects and encourage independent initiatives to develop the entrepreneurial community while reinforcing cooperation between Jerusalem's outstanding academic environment and the innovation scene. Jnext directly supports companies through every stage of their development to allow them to grow and flourish in the city. The initiative was first established in 2012 with government funding of just $20 million for the first five years. In light of the major impact Jnext's activities and support have had, this budget has been increased to $100 million for the next five-year period. http://www.jnext.org.il/about/